RXST
RxSight, Inc. · Healthcare · Medical - Devices
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +5.5% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 70 | -7 | 30.76M | $148.37M | +3 | −9 |
| Q1 2026 | 78 | +10 | 29.02M | $178.70M | +11 | −1 |
| Q4 2025 | 68 | 0 | 28.07M | $292.47M | +1 | −1 |
| Q3 2025 | 17 | 0 | 14.88M | $133.76M | +1 | −1 |
| Q2 2025 | 14 | 0 | 12.67M | $164.75M | +1 | −1 |
| Q1 2025 | 11 | -1 | 4.08M | $103.15M | — | −1 |
| Q4 2024 | 12 | 0 | 5.10M | $175.38M | — | — |
| Q3 2024 | 11 | -1 | 3.15M | $155.64M | — | −1 |
| Q2 2024 | 12 | — | 2.73M | $164.29M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 2.70M | -10.1% | $24.30M | 0.0% | ▼ Trim | 2 | SEC ↗ ×8 |
| 2 | Millennium Management ✦ | 2.19M | +130.6% | $19.72M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 3 | The Vanguard Group ✦ (passive) | 2.15M | -5.8% | $19.30M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 4 | D. E. Shaw & Co. ✦ | 1.83M | +38.8% | $16.49M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 5 | Citadel Advisors ✦ | 1.29M | +25.5% | $11.60M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 6 | Morgan Stanley ✦ | 844.65K | — | $7.59M | 0.0% | n/c | 1 | SEC ↗ ×9 |
| 7 | State Street Global Advisors ✦ (passive) | 824.14K | -10.1% | $7.41M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passive) | 739.30K | -14.3% | $6.65M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 9 | Baillie Gifford ✦ | 686.32K | +46.4% | $6.17M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 10 | Two Sigma Investments ✦ | 662.42K | +50.4% | $5.96M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 11 | Goldman Sachs Group ✦ | 373.55K | — | $3.36M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 12 | JPMorgan Chase ✦ | 205.76K | — | $1.85M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 13 | Point72 Asset Management ✦ | 155.29K | New | $1.40M | 0.0% | New | 1 | SEC ↗ |
| 14 | Renaissance Technologies ✦ | 138.70K | -67.5% | $1.25M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 33.53K | +45.1% | $302,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 26.04K | -59.5% | $234,074 | 0.0% | ▼ Trim | 6 | SEC ↗ ×5 |
| 17 | Fidelity (FMR) ✦ | 21.48K | -86.3% | $193,122 | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $1.40M | 0.0% |
Exited
| Wellington Management | $9.46M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 162 holders, 37.72M shares, $223.80M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.04K sh · $14,205
Officer · 5.10K sh · $35,496
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology